What is she best known for?
The fields of study she is best known for:
- Gene
- Cancer
- Internal medicine
Claudia Haferlach mainly focuses on Internal medicine, Leukemia, Myeloid leukemia, Myeloid and Cancer research.
Her studies deal with areas such as Gastroenterology, Immunology, Oncology and Cytogenetics as well as Internal medicine.
Her work carried out in the field of Leukemia brings together such families of science as Myeloproliferative neoplasm, Mutation, Gene mutation, Neuroblastoma RAS viral oncogene homolog and Survival analysis.
Her Myeloid leukemia study integrates concerns from other disciplines, such as Chronic myelogenous leukemia, Surgery and NPM1.
Her study ties her expertise on Myelodysplastic syndromes together with the subject of Myeloid.
Her work deals with themes such as Acute lymphocytic leukemia and B cell, which intersect with Cancer research.
Her most cited work include:
- Frequent pathway mutations of splicing machinery in myelodysplasia (1387 citations)
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes (791 citations)
- BRAF mutations in hairy-cell leukemia (749 citations)
What are the main themes of her work throughout her whole career to date?
Claudia Haferlach focuses on Leukemia, Internal medicine, Oncology, Myeloid leukemia and Genetics.
Her Leukemia study incorporates themes from Myeloid, Cancer research, NPM1 and Cytogenetics.
Her research in Cancer research intersects with topics in Cancer and Fusion gene.
Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Karyotype and Pathology.
Her Oncology research includes themes of Transplantation, Bioinformatics, Minimal residual disease, Chronic lymphocytic leukemia and Cohort.
Claudia Haferlach works in the field of Myeloid leukemia, namely Imatinib.
She most often published in these fields:
- Leukemia (48.55%)
- Internal medicine (43.54%)
- Oncology (27.31%)
What were the highlights of her more recent work (between 2017-2021)?
- Leukemia (48.55%)
- Cancer research (21.90%)
- Internal medicine (43.54%)
In recent papers she was focusing on the following fields of study:
Her scientific interests lie mostly in Leukemia, Cancer research, Internal medicine, Myeloid leukemia and Myeloid.
Her Leukemia study combines topics in areas such as Mutation, Young adult, NPM1 and Chromosome abnormality.
Her Cancer research research is multidisciplinary, relying on both RNA, Transcription factor and Gene expression, DNA methylation.
The Internal medicine study combines topics in areas such as Gastroenterology, Oncology and Karyotype.
Her biological study spans a wide range of topics, including Exome sequencing and Myelogenous.
Her Myeloid research includes elements of MECOM and Minimal residual disease.
Between 2017 and 2021, her most popular works were:
- TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (64 citations)
- Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact (49 citations)
- MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. (38 citations)
In her most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Internal medicine, Leukemia, Myeloid leukemia, Myeloid and Oncology are her primary areas of study.
The various areas that Claudia Haferlach examines in her Internal medicine study include Gastroenterology and Chromosome 7.
Her Leukemia research is multidisciplinary, incorporating perspectives in Young adult, CCAAT/enhancer binding protein alpha and Chimera.
Myeloid leukemia is a subfield of Cancer research that Claudia Haferlach investigates.
Her Myeloid study combines topics from a wide range of disciplines, such as Genetics, NPM1, PDGFRB and Pathology.
Claudia Haferlach has included themes like Survival rate, Treatment strategy, Imatinib and Cancer in her Oncology study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
